[1]
Beynon ME,Pinneri K, An Overview of the Thyroid Gland and Thyroid-Related Deaths for the Forensic Pathologist. Academic forensic pathology. 2016 Jun;
[PubMed PMID: 31239894]
Level 3 (low-level) evidence
[4]
Tamhane S,Gharib H, Thyroid nodule update on diagnosis and management. Clinical diabetes and endocrinology. 2016;
[PubMed PMID: 28702251]
[5]
Xie C,Cox P,Taylor N,LaPorte S, Ultrasonography of thyroid nodules: a pictorial review. Insights into imaging. 2016 Feb;
[PubMed PMID: 26611469]
[6]
Martelli ML,Iuliano R,Le Pera I,Sama' I,Monaco C,Cammarota S,Kroll T,Chiariotti L,Santoro M,Fusco A, Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. The Journal of clinical endocrinology and metabolism. 2002 Oct;
[PubMed PMID: 12364466]
[7]
Wang Q,Shen Y,Ye B,Hu H,Fan C,Wang T,Zheng Y,Lv J,Ma Y,Xiang M, Gene expression differences between thyroid carcinoma, thyroid adenoma and normal thyroid tissue. Oncology reports. 2018 Dec
[PubMed PMID: 30272326]
[8]
Hossain MA,Asa TA,Rahman MM,Uddin S,Moustafa AA,Quinn JMW,Moni MA, Network-Based Genetic Profiling Reveals Cellular Pathway Differences Between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma. International journal of environmental research and public health. 2020 Feb 20
[PubMed PMID: 32093341]
[9]
García-Vence M,Chantada-Vázquez MDP,Cameselle-Teijeiro JM,Bravo SB,Núñez C, A Novel Nanoproteomic Approach for the Identification of Molecular Targets Associated with Thyroid Tumors. Nanomaterials (Basel, Switzerland). 2020 Nov 28
[PubMed PMID: 33260544]
[10]
Bisi H,Fernandes VS,de Camargo RY,Koch L,Abdo AH,de Brito T, The prevalence of unsuspected thyroid pathology in 300 sequential autopsies, with special reference to the incidental carcinoma. Cancer. 1989 Nov 1;
[PubMed PMID: 2676140]
[11]
Rochau U,Qerimi Rushaj V,Schaffner M,Schönhensch M,Stojkov I,Jahn B,Hubalewska-Dydejczyk A,Erlund I,Thuesen BH,Zimmermann M,Moreno-Reyes R,Lazarus JH,Völzke H,Siebert U, Decision-analytic Modeling Studies in Prevention and Treatment of Iodine Deficiency Disorders and Thyroid Disorders: a Systematic Overview. Thyroid : official journal of the American Thyroid Association. 2020 Jan 22;
[PubMed PMID: 31964247]
Level 3 (low-level) evidence
[12]
Challeton C,Bounacer A,Du Villard JA,Caillou B,De Vathaire F,Monier R,Schlumberger M,Suárez HG, Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors. Oncogene. 1995 Aug 3;
[PubMed PMID: 7630645]
[13]
Jeong SH,Hong HS,Lee EH,Kwak JJ,Lee JY, Analysis of {i}RAS{/i} mutation in thyroid nodular hyperplasia and follicular neoplasm in a Korean population. Endocrinology, diabetes
[PubMed PMID: 30815568]
[14]
Saglietti C,Piana S,La Rosa S,Bongiovanni M, Hyalinizing trabecular tumour of the thyroid: fine-needle aspiration cytological diagnosis and correlation with histology. Journal of clinical pathology. 2017 Aug;
[PubMed PMID: 28424236]
[16]
Baloch ZW,Asa SL,Barletta JA,Ghossein RA,Juhlin CC,Jung CK,LiVolsi VA,Papotti MG,Sobrinho-Simões M,Tallini G,Mete O, Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine pathology. 2022 Mar
[PubMed PMID: 35288841]
Level 3 (low-level) evidence
[17]
Mariani G,Tonacchera M,Grosso M,Orsolini F,Vitti P,Strauss HW, The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2021 Mar
[PubMed PMID: 33008929]
[18]
D'Avanzo A,Treseler P,Ituarte PH,Wong M,Streja L,Greenspan FS,Siperstein AE,Duh QY,Clark OH, Follicular thyroid carcinoma: histology and prognosis. Cancer. 2004 Mar 15;
[PubMed PMID: 15022277]
[19]
Collini P,Sampietro G,Rosai J,Pilotti S, Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma. Virchows Archiv : an international journal of pathology. 2003 Jan
[PubMed PMID: 12536317]
Level 3 (low-level) evidence
[20]
Borowczyk M,Woliński K,Więckowska B,Jodłowska-Siewert E,Szczepanek-Parulska E,Verburg FA,Ruchała M, Sonographic Features Differentiating Follicular Thyroid Cancer from Follicular Adenoma-A Meta-Analysis. Cancers. 2021 Feb 24
[PubMed PMID: 33668130]
Level 1 (high-level) evidence
[21]
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association. 2016 Jan:26(1):1-133. doi: 10.1089/thy.2015.0020. Epub
[PubMed PMID: 26462967]
[22]
Hu XY,Wu J,Seal P,Ghaznavi SA,Symonds C,Kinnear S,Paschke R, Improvement in thyroid ultrasound report quality with radiologists' adherence to 2015 ATA or 2017 TIRADS: a population study. European thyroid journal. 2022 Jun 14;
[PubMed PMID: 35521979]
Level 2 (mid-level) evidence
[23]
Grani G,Lamartina L,Ascoli V,Bosco D,Biffoni M,Giacomelli L,Maranghi M,Falcone R,Ramundo V,Cantisani V,Filetti S,Durante C, Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the
[PubMed PMID: 30299457]
[24]
Castellana M,Grani G,Radzina M,Guerra V,Giovanella L,Deandrea M,Ngu R,Durante C,Trimboli P, Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules: a meta-analysis. European journal of endocrinology. 2020 Sep;
[PubMed PMID: 32544875]
Level 1 (high-level) evidence
[25]
Koc AM,Adıbelli ZH,Erkul Z,Sahin Y,Dilek I, Comparison of diagnostic accuracy of ACR-TIRADS, American Thyroid Association (ATA), and EU-TIRADS guidelines in detecting thyroid malignancy. European journal of radiology. 2020 Dec
[PubMed PMID: 33181485]
[26]
Collins J,Rossi ED,Chandra A,Ali SZ, Terminology and nomenclature schemes for reporting thyroid cytopathology: An overview. Seminars in diagnostic pathology. 2015 Jul;
[PubMed PMID: 25680862]
Level 3 (low-level) evidence
[27]
Vargas-Salas S,Martínez JR,Urra S,Domínguez JM,Mena N,Uslar T,Lagos M,Henríquez M,González HE, Genetic testing for indeterminate thyroid cytology: review and meta-analysis. Endocrine-related cancer. 2018 Mar
[PubMed PMID: 29255094]
Level 1 (high-level) evidence
[28]
Jug RC,Datto MB,Jiang XS, Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel. Cancer cytopathology. 2018 Jul
[PubMed PMID: 29637728]
[29]
Rossi ED,Pantanowitz L,Faquin WC, The Role of Molecular Testing for the Indeterminate Thyroid FNA. Genes. 2019 Sep 23
[PubMed PMID: 31547603]
[30]
Livhits MJ,Kuo EJ,Leung AM,Rao J,Levin M,Douek ML,Beckett KR,Zanocco KA,Cheung DS,Gofnung YA,Smooke-Praw S,Yeh MW, Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules. The Journal of clinical endocrinology and metabolism. 2018 Jun 1
[PubMed PMID: 29590358]
[31]
Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, Gomes-Lima C, Ferris RL, Folek JM, Khawaja RA, Kundra P, Loh KS, Marshall CB, Mayson S, McCoy KL, Nga ME, Ngiam KY, Nikiforova MN, Poehls JL, Ringel MD, Yang H, Yip L, Nikiforov YE. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA oncology. 2019 Feb 1:5(2):204-212. doi: 10.1001/jamaoncol.2018.4616. Epub
[PubMed PMID: 30419129]
Level 2 (mid-level) evidence
[32]
Li W,Song Q,Lan Y,Li J,Zhang Y,Yan L,Li Y,Zhang Y,Luo Y, The Value of Sonography in Distinguishing Follicular Thyroid Carcinoma from Adenoma. Cancer management and research. 2021;
[PubMed PMID: 34040440]
[33]
Miccoli P,Minuto MN,Galleri D,D'Agostino J,Basolo F,Antonangeli L,Aghini-Lombardi F,Berti P, Incidental thyroid carcinoma in a large series of consecutive patients operated on for benign thyroid disease. ANZ journal of surgery. 2006 Mar;
[PubMed PMID: 16626346]
[34]
Sharma A,Abraham D, VASCULARITY-TARGETED PERCUTANEOUS ETHANOL INJECTION OF TOXIC THYROID ADENOMAS: OUTCOMES OF A FEASIBILITY STUDY PERFORMED IN THE USA. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2020 Jan;
[PubMed PMID: 31461356]
Level 2 (mid-level) evidence
[35]
Marques AR,Espadinha C,Catarino AL,Moniz S,Pereira T,Sobrinho LG,Leite V, Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. The Journal of clinical endocrinology and metabolism. 2002 Aug;
[PubMed PMID: 12161538]
[36]
Kitahara CM,K Rmendiné Farkas D,Jørgensen JOL,Cronin-Fenton D,Sørensen HT, Benign Thyroid Diseases and Risk of Thyroid Cancer: A Nationwide Cohort Study. The Journal of clinical endocrinology and metabolism. 2018 Jun 1
[PubMed PMID: 29590402]
[39]
Tan GH,Gharib H, Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Annals of internal medicine. 1997 Feb 1;
[PubMed PMID: 9027275]
[40]
Schneider AB,Sarne DH, Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nature clinical practice. Endocrinology
[PubMed PMID: 16929376]